Mikrobiomik Health Company has set a new milestone by being recognised twice at the Quality Innovation Awards (QIA) 2024 in the international phase: Best Innovation in the Healthcare Sector and the competition’s top award, Innovation of Innovations, from among all the participating categories.
In this 18th global edition, a total of 557 innovations participated, of which only 23 were awarded after a rigorous international evaluation process, presided over by the Chinese Association for Quality. Among the criteria considered were innovation, usability, customer orientation, effectiveness, and learning, with companies from different countries such as China, Hungary, Finland, Thailand, Turkey and Spain receiving awards.
MBK-01 is the award-winning innovation, an investigational biological medicine based on gut microbiota, designed to treat severe Clostridioides difficile infections without the use of conventional antibiotic treatments. This pioneering therapy represents a significant advance in the battle against antimicrobial resistance, and a safe and effective solution for thousands of patients.
The international QIA awards are given to projects that reach this global stage after being awarded in national stages, with eight different categories and a top award for the best innovation in all categories. Mikrobiomik has been chosen as Innovation of Innovations, which places the company as a world leader in healthcare innovation.
The official award ceremony will be held in May 2025 in Bangkok and will be organized by the Productivity Institute of Thailand, where Mikrobiomik will represent the Basque Country and Spain.
This milestone highlights the company’s commitment to the pursuit of excellence, always with the focus on improving the quality of life of patients and contributing to the sustainability of the healthcare system.
For more information on the awards and the full list of winners, please visit Quality Innovation Awards
